Doravirine

Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC50s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively[1].

Product Specifications

CAS Number

[1338225-97-0]

Product Name Alternative

MK-1439

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Doravirine.html

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC1=CC(OC2=C(C(F)(F)F)C=CN(CC(N3C)=NNC3=O)C2=O)=CC(Cl)=C1

Molecular Formula

C17H11ClF3N5O3

Molecular Weight

425.75

Precautions

H315, H319, H320

References & Citations

[1]Lai MT et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58 (3) :1652-63.|[2]Anderson MS et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20 (4) :397-405.